Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer-Reference-Cited by-同舟云学术

Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer

Published:2019-08-19 Issue:13 Volume:8 Page:5891-5902
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Suzuki Hiroyoshi¹,Uemura Hiroji²,Mizokami Atsushi³,Hayashi Narihiko⁴,Miyoshi Yasuhide²,Nagamori Satoshi⁵,Enomoto Yutaka⁶,Akaza Hideyuki⁷,Asato Takayuki⁸^ORCID,Kitagawa Tadayuki⁹,Suzuki Kazuhiro¹⁰

Affiliation:

1. Department of Urology Toho University Sakura Medical Center Chiba Japan

2. Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan

3. Department of Integrative Cancer Therapy and Urology Graduate School of Medical Sciences Kanazawa University Kanazawa Japan

4. Department of Urology Public University Corporation Yokohama City University Hospital Yokohama Japan

5. Department of Urology Incorporated Administrative Agency National Hospital Organization Hokkaido Cancer Center Sapporo Japan

6. Department of Urology Mitsui Memorial Hospital Tokyo Japan

7. Department of Strategic Investigation on Comprehensive Cancer Network Interfaculty Initiative in Information Studies/Graduate School of Interdisciplinary Information Studies The University of Tokyo Tokyo Japan

8. Oncology Clinical Research Department Oncology Therapeutic Area Unit for Japan and Asia Takeda Pharmaceutical Company Limited Osaka Japan

9. Japan Development Center Takeda Pharmaceutical Company Limited Osaka Japan

10. Department of Urology Graduate School of Medicine National University Corporation Gunma University Maebashi Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2442

Reference32 articles.

1. Foundation for Promotion of Cancer Research.Cancer statistics in Japan 2017.https://ganjoho.jp/en/professional/statistics/brochure/2017_en.html. Accessed April 5 2018.

2. Risk and preventive factors for prostate cancer in Japan: The Japan Public Health Center-based prospective (JPHC) study

3. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies;Haas GP;Can J Urol,2008

4. International Longevity Center Japan.Aging in Japan: a profile of older Japanese.2013.http://www.ilcjapan.org/agingE/POJ13.html. Accessed March 26 2018.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol;Future Oncology;2024-03-15

2. Data Mining and Analysis for Safety Signals of Degarelix Based on FAERS;Pharmacy Information;2024

3. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study;European Urology;2023-12

4. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer;Cancers;2023-10-05

5. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy;Drug Design, Development and Therapy;2023-08